Search Result

Pathways Recommended:	Stem Cell/Wnt Cell Cycle/DNA Damage

Results for "

malignant human cells

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Payload (1) Akt (1) Anaplastic lymphoma kinase (ALK) (3) Apoptosis (8) Autophagy (2) Bacterial (1) Bcl-2 Family (2) Biochemical Assay Reagents (2) c-Kit (1) Caspase (1) CCR (1) CD20 (1) CD3 (1) CDK (1) CTLA-4 (1) Cyclin G-associated Kinase (GAK) (1) DNA/RNA Synthesis (1) Drug Derivative (2) Drug Metabolite (1) Endogenous Metabolite (1) ERK (1) Fc Receptor (FcR) (1) Ferroptosis (1) Glutathione S-transferase (1) HBV (1) HCV (1) HDAC (1) HSP (1) Interleukin Related (1) JNK (1) Microtubule/Tubulin (2) MMP (1) mTOR (1) NF-κB (2) P-glycoprotein (1) p38 MAPK (2) PI3K (1) PROTACs (1) Radionuclide-Drug Conjugates (RDCs) (1) Reactive Oxygen Species (ROS) (1) Reference Standards (1) STAT (1) Survivin (1) TNF Receptor (3) Topoisomerase (3) Transmembrane Glycoprotein (3)
By Research Areas:	Cancer (27) Cardiovascular Disease (2) Infection (2) Inflammation/Immunology (5)

By Targets:

ADC Payload (1)

Akt (1)

Anaplastic lymphoma kinase (ALK) (3)

Apoptosis (8)

Autophagy (2)

Bacterial (1)

Bcl-2 Family (2)

Biochemical Assay Reagents (2)

c-Kit (1)

Caspase (1)

CCR (1)

CD20 (1)

CD3 (1)

CDK (1)

CTLA-4 (1)

Cyclin G-associated Kinase (GAK) (1)

DNA/RNA Synthesis (1)

Drug Derivative (2)

Drug Metabolite (1)

Endogenous Metabolite (1)

ERK (1)

Fc Receptor (FcR) (1)

Ferroptosis (1)

Glutathione S-transferase (1)

HBV (1)

HCV (1)

HDAC (1)

HSP (1)

Interleukin Related (1)

JNK (1)

Microtubule/Tubulin (2)

MMP (1)

mTOR (1)

NF-κB (2)

P-glycoprotein (1)

p38 MAPK (2)

PI3K (1)

PROTACs (1)

Radionuclide-Drug Conjugates (RDCs) (1)

Reactive Oxygen Species (ROS) (1)

Reference Standards (1)

STAT (1)

Survivin (1)

TNF Receptor (3)

Topoisomerase (3)

Transmembrane Glycoprotein (3)

By Research Areas:

Cancer (27)

Cardiovascular Disease (2)

Infection (2)

Inflammation/Immunology (5)

Inhibitors & Agonists

Screening Libraries

Inhibitory Antibodies

Natural
Products

Targets Recommended: Nuclear Factor of activated T Cells (NFAT) TREM receptor

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-19824

3PO 25+ Cited Publications	Autophagy	Cancer
3PO is an inhibitor of PFKFB3. 3PO attenuates the proliferation of several cancer cell lines with IC₅₀s of 1.4-24 μmol/L. 3PO suppresses glucose uptake and decreases the intracellular concentration of Fru-2,6-BP, lactate, ATP, NAD ⁺ and NADH. 3PO can be used for the research of cancer .

HY-B0766

Bicyclol SY801	Autophagy Apoptosis HBV HCV HSP Reactive Oxygen Species (ROS) Bcl-2 Family Glutathione S-transferase p38 MAPK NF-κB Microtubule/Tubulin ERK JNK TNF Receptor Interleukin Related CDK Cyclin G-associated Kinase (GAK) mTOR P-glycoprotein Ferroptosis	Infection Inflammation/Immunology Cancer
Bicyclol (SY801) is an orally active derivative of the traditional Chinese medicine Schisandra chinensis, which has antiviral, anti-inflammatory, immunomodulatory, antioxidant, anti-steatosis, anti-fibrotic and anti-tumor activities. Bicyclol regulates the expression of heat shock proteins and plays an anti-apoptosis role in hepatocytes. Bicyclol reduces the activation of NF-κB and the levels of inflammatory factors in hepatocytes infected with hepatitis C virus (HCV) by inhibiting the activation of the ROS-MAPK-NF-κB pathway, and prevents ferroptosis in acute liver injury. Bicyclol can change the expression of Mdr-1, GSH/GST and Bcl-2, increase the intracellular concentration of anticancer drugs, and sensitize drug-resistant cells to anticancer drugs. Bicyclol inhibits the proliferation of human malignant hepatoma cells by regulating the PI3K/AKT pathway and the Ras/Raf/MEK/ERK pathway. Bicyclol can be used in the study of chronic hepatitis, acute liver injury, nonalcoholic fatty liver disease, liver fibrosis and hepatocellular carcinoma .

HY-N4114

Picrocrocin	Apoptosis	Cancer
Picrocrocin, an apocarotenoid found in Saffron. Picrocrocin shows anticancer effect. Picrocrocin exhibits growth inhibitory effects against SKMEL-2 human malignant melanoma cells .

HY-P991155

Ramantamig JNJ-79635322; JNJ-5322	CD3 TNF Receptor	Cancer
Ramantamig (JNJ-79635322) is a humanized monoclonal antibody targeting human CD3ε, GPRC5D, and TNFRSF17 (BCMA). Ramantamig binds to BCMA and GPRC5D on multiple myeloma cells, binds to CD3ε on T cells, forms immunological synapses, and enables T-cell-mediated cytotoxicity. Ramantamig activates T cells concomitantly with inducing myeloma cell cytotoxicity, with no nonspecific T-cell activation in the absence of target myeloma cells. Ramantamig carries mutations to reduce interaction with Fc receptors and disrupt protein A binding of monomeric and homodimerized chains. Ramantamig can be used for the research of multiple myeloma .

HY-13631J

(1R,9R)-Exatecan mesylate (1R,9R)-DX8951f	Drug Derivative Topoisomerase Apoptosis	Cancer
(1R,9R)-Exatecan mesylate ((1R,9R)-DX8951f) is a non-prodrug camptothecin derivative and a potent topoisomerase I inhibitor (IC₅₀=0.975 μg/mL in mice and 0.82 μg/mL in humans). (1R,9R)-Exatecan mesylate blocks enzyme activity and induces apoptosis by stabilizing the enzyme-DNA cleavable complex. (1R,9R)-Exatecan mesylate not only effectively inhibits the proliferation of various malignant tumor cells and tumor growth, but also circumvents P-glycoprotein-mediated multidrug resistance. (1R,9R)-Exatecan mesylate is widely used in preclinical studies of multiple cancers including pancreatic cancer, lung cancer, breast cancer, and leukemia . The low-activity isomer of (1R,9R)-Exatecan mesylate is (1S,9R)-Exatecan mesylate (HY-13631I).

HY-P99781

Plozalizumab MLN-1202	CCR	Inflammation/Immunology Cancer
Plozalizumab (MLN-1202) is a humanized anti-CCR2 IgG1 monoclonal antibody. Plozalizumab blocks the recruitment of myeloid cells to the tumor microenvironment by inhibiting the CCL2/CCR2 axis. In addition, Plozalizumab also ameliorates synovial inflammation in rheumatoid arthritis. Plozalizumab can be used in the research of malignant melanoma and bone metastasis-related cancers. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-13631I

(1S,9R)-Exatecan mesylate (1S,9R)-DX8951f	Drug Derivative Topoisomerase Apoptosis	Cancer
(1S,9R)-Exatecan mesylate ((1S,9R)-DX8951f) is a non-prodrug camptothecin derivative and a topoisomerase I inhibitor (IC₅₀=0.975 μg/mL in mice and 0.82 μg/mL in humans). (1S,9R)-Exatecan mesylate blocks enzyme activity and induces apoptosis by stabilizing the enzyme-DNA cleavable complex. (1S,9R)-Exatecan mesylate not only effectively inhibits the proliferation of various malignant tumor cells and tumor growth, but also circumvents P-glycoprotein-mediated multidrug resistance. (1S,9R)-Exatecan mesylate is widely used in preclinical studies of various cancers such as pancreatic cancer, lung cancer, breast cancer, and leukemia . The chiral isomer of (1S,9R)-Exatecan mesylate is (1R,9R)-Exatecan mesylate (HY-13631J).

HY-148819A

NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT hydrochloride	ADC Payload Topoisomerase	Cancer
NH2-bicyclopentane-7-MAD-MDCPT hydrochloride (Formula I) is a topoisomerase I (TOP1) inhibitor. NH2-bicyclopentane-7-MAD-MDCPT hydrochloride is applicable to the synthesis of the ADC ABBV-969. NH2-bicyclopentane-7-MAD-MDCPT hydrochloride is used in research on lung adenocarcinoma and melanoma .

HY-143411

GEM144	HDAC Apoptosis DNA/RNA Synthesis	Cancer
GEM144 is a potent and orally active DNA polymerase α (POLA1) and HDAC 11 dual inhibitor. GEM144 induces acetylation of p53, activation of p21, G1/S cell cycle arrest, and apoptosis. GEM144 has significant antitumor activity in human orthotopic malignant pleural mesothelioma xenografts .

HY-P991225

BI-1206	Fc Receptor (FcR) CD20	Inflammation/Immunology Cancer
BI-1206 is a recombinant and antagonistic human monoclonal antibody targeting FcγRIIB (CD32B). BI-1206 can block CD20 internalization induced by Rituximab (HY-P9913) itself or combined with others including Ibrutinib (HY-10997), Venetoclax (HY-15531), and CHOP. BI-1206 can enhance or recover the activity of Rituximab or other anti-CD20 monoclonal antibodies. BI-1206 has cytolytic activity against malignant B cells. BI-1206 can be studied for cancer research such as mantle cell lymphoma (MCL) .

HY-N4114R

Picrocrocin (Standard)	Reference Standards Apoptosis	Cancer
Picrocrocin (Standard) is the analytical standard of Picrocrocin. This product is intended for research and analytical applications. Picrocrocin, an apocarotenoid found in Saffron. Picrocrocin shows anticancer effect. Picrocrocin exhibits growth inhibitory effects against SKMEL-2 human malignant melanoma cells .

HY-177275

c-Kit Receptor modulator-1	c-Kit	Cancer
c-Kit Receptor modulator-1 (Compound #22) is a c-Kit Receptor modulator. c-Kit Receptor modulator-1 can be used for malignant cancers such as canine mastocytoma, human gastrointestinal stromal tumor and small cell lung cancer research .

HY-174336

Survivin-IN-1	Survivin Apoptosis	Cancer
Survivin-IN-1 (Compound II₃) is a potent Survivin (a member of the Inhibitor of Apoptosis Protein family) inhibitor with an IC₅₀ value of 8.1 μM against human lung cancer A549 cells and 9.0 μM against breast cancer MCF-7 cells. Survivin-IN-1 reduces Survivin protein levels and induces tumor cell apoptosis. Survivin-IN-1 is promising for research of malignant tumors such as lung cancer and breast cancer .

HY-147706

AR524	Others	Cancer
Ar524 has higher inhibitory activity than the known transgenic inhibitor kifunensine. At the same time, ar524 inhibited low concentration (10 μ M) Spheroid formation of human malignant cells.

HY-P991425

AT-1413	Transmembrane Glycoprotein	Cancer
AT-1413 is a human monoclonal antibody (mAb) targeting CD43. AT-1413 induces antibody-dependent cell-mediated cytotoxicity (ADCC) in melanoma cell lines and acute myeloid leukemia (AML) cells. AT-1413 has antitumor activity in AML mouse models. AT-1413 can be used in Acute myeloid leukaemia, Breast cancer, Malignant melanoma and Myelodysplastic syndromes research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-E70760

NPM1 ALK Recombinant Human Active Protein Kinase	Anaplastic lymphoma kinase (ALK)	Cancer
The NPM1-ALK protein contains the NPM1 oligomerization motif and the ALK catalytic domain, is constitutively activated through autophosphorylation, and mediates malignant cell transformation by activating downstream effectors including STAT3. NPM1 ALK Recombinant Human Active Protein Kinase is a recombinant NPM1 ALK protein that can be used to study NPM1 ALK-related functions .

HY-145533A

3-Deoxy-D-glycero-D-galacto-2-nonulosonic acid sodium KDN sodium	Endogenous Metabolite	Others
3-Deoxy-D-glycero-D-galacto-2-nonulosonic acid (KDN) sodium is a sialic acid. 3-Deoxy-D-glycero-D-galacto-2-nonulosonic acid sodium protects the oligo/(poly)sialyl chains from exosialidases at nonreducing terminal, and plays a role in egg activation of salmonid fish. 3-Deoxy-D-glycero-D-galacto-2-nonulosonic acid sodium is abundant in fetal cord red blood cells and malignant human ovarian cancer cells .

HY-E70761

NPM1 ALK F1174L Recombinant Human Active Protein Kinase	Anaplastic lymphoma kinase (ALK)	Cancer
The NPM1-ALK protein contains the NPM1 oligomerization motif and the ALK catalytic domain, is constitutively activated through autophosphorylation, and mediates malignant cell transformation by activating downstream effectors including STAT3. NPM1 ALK F1174L Recombinant Human Active Protein Kinase is a recombinant NPM1 ALK F1174L protein that can be used to study NPM1 ALK F1174L-related functions .

HY-155995

PRO-905 MK-905	Biochemical Assay Reagents	Cancer
Pro-905 is a phosphite peptide with antitumor activity. Pro-905 delivers the active nucleotide antimetabolite thioguanosine monophosphate (TGMP) to the tumor. Pro-905 effectively prevents incorporation of purine salvage substrates into nucleic acids and inhibits colony formation in human malignant peripheral nerve sheath tumors (MPNST) cells. Pro-905 inhibits purine salvage incorporation to nucleic acids and prevents cell growth. Pro-905 inhibits the growth of MPNST and enhances the anti-tumor efficacy of JHU395 (HY-124778) .

HY-182478

MDL-27048	Microtubule/Tubulin	Cancer
MDL-27048, a tubulin inhibitor, binds competitively, reversibly to the Colchicine (HY-16569)-binding site on tubulin heterodimers. MDL-27048 inhibits microtubule assembly, induces slow depolymerization of preassembled microtubules, disrupts microtubule polymerization-depolymerization dynamics, and disrupts cytoplasmic microtubule networks. MDL-27048 exerts growth inhibitory effects on human cancer cells, induces mitotic arrest, and does not disrupt actin filaments at microtubule-depolymerizing concentrations. MDL-27048 can be used for the research of malignant tumors .

HY-P992430

OI-3	Transmembrane Glycoprotein Radionuclide-Drug Conjugates (RDCs)	Inflammation/Immunology Cancer
OI-3 is a monoclonal antibody targeting CD146 (MCAM). OI-3 specifically binds to CD146 on the surface of human mesothelioma cells and undergoes endocytosis; both chimeric (chOI-3) and murine (mOI-3) variants possess this activity. When conjugated with ²¹²Pb to form ²¹²Pb-TCMC-OI-3, OI-3 acts as a cytotoxic agent that delivers α-emitting radionuclides to induce targeted cytotoxicity. OI-3 can be used in research related to malignant peritoneal mesothelioma .

HY-P992404

MDX-1401	TNF Receptor	Cancer
MDX-1401 is a fully human IgG1 (κ isotype) monoclonal antibody against CD30, with a K_d value of 0.83 nmol/L. MDX-1401 induces antibody-dependent cellular cytotoxicity in CD30-expressing cells and inhibits tumor growth in CD30 ⁺ lymphoma xenograft models. MDX-1401 can be used in research related to malignant lymphoma and Hodgkin lymphoma .

HY-P991959

JMW-3B3	CTLA-4	Inflammation/Immunology Cancer
JMW-3B3 is a humanized IgG1λ monoclonal antibody targeting CTLA-4. JMW-3B3 selectively binds the unique C-terminal sequence of sCTLA-4 to block its immunoregulatory and immunosuppressive activity without cross-reacting with full-length CTLA-4 receptor. JMW-3B3 enhances cytokine profiles in PBMC cultures responding to lupus autoantigen-derived peptides. JMW-3B3 enhances IFN-γ production in anti-CD3 stimulated PBMC from melanoma patients at low anti-CD3 doses. JMW-3B3 can be used for the research of systemic lupus erythematosus and malignant melanoma.

HY-180956

PROTAC ALK degrader-5	PROTACs Anaplastic lymphoma kinase (ALK) STAT	Cancer
PROTAC ALK degrader-5 (Compound 17) is an efficient ALK PROTAC degrader, with its inhibitory effects on EML4-ALK and NPM-ALK being 27.4 nM and 116.5 nM respectively. PROTAC ALK degrader-5 exhibits potent anti-proliferative activity against H3122 and Karpas 299. PROTAC ALK degrader-5 effectively inhibits the phosphorylation of ALK and STAT3. PROTAC ALK degrader-5 can be used for the study of ALK-driven malignant tumors, such as human non-small cell lung cancer and anaplastic large cell lymphoma .

HY-N18009

1-Hydroxy-3,5-dimethoxyxanthone	Bacterial	Infection Cancer
1-Hydroxy-3,5-dimethoxyxanthone is a xanthone and Antibacterial agent. 1-Hydroxy-3,5-dimethoxyxanthone can be isolated from Lomatogonium rotatum. 1-Hydroxy-3,5-dimethoxyxanthone inhibits the growth of Pseudomonas aeruginosa ATCC27853 and Escherichia coli ATCC25923 with an MIC of 640 μg/mL. 1-Hydroxy-3,5-dimethoxyxanthone exhibits anticancer activity against cervical cancer, breast cancer, melanoma, liver cancer, and gastric cancer .

HY-186206

(Rac)-EGC-M7	Drug Metabolite	Cancer
(Rac)-EGC-M7 is a racemic microbial metabolite of green tea Catechin (EGC) (HY-N0898), and acts as an inhibitor of nitric oxide production and cancer cell growth. (Rac)-EGC-M7 can be used in the research of esophageal squamous cell carcinoma and colon adenocarcinoma .

HY-P992200

Anti-CD146 Antibody (AA98)	Transmembrane Glycoprotein PI3K Akt p38 MAPK NF-κB MMP Apoptosis Caspase Bcl-2 Family	Cardiovascular Disease Cancer
Anti-CD146 Antibody (AA98) is an antibody targeting CD146 and an angiogenesis inhibitor. Anti-CD146 Antibody (AA98) blocks the dimerization of CD146 as well as its downstream PI3K/AKT, p38 MAPK and NF-κB signaling pathways; it inhibits the expression of MMP9 and ICAM1, epithelial-mesenchymal transition (EMT), and the proliferation, migration and tube formation of endothelial cells. Anti-CD146 Antibody (AA98) enhances radiation-induced cancer cell apoptosis and survival inhibition, reduces tumor microvessel density, and suppresses tumor growth, invasion and vasculogenic mimicry. Anti-CD146 Antibody (AA98) can be used in research related to cervical cancer, liver cancer, malignant phyllodes tumor of the breast, uveal melanoma, leiomyosarcoma, pancreatic cancer, other tumors and angiogenesis .

HY-182501

HSC mobilizer-1	Biochemical Assay Reagents	Cardiovascular Disease
HSC mobilizer-1 (Compound 3) is an in vitro expansion activator of HSC. HSC mobilizer-1 promotes the in vitro expansion of hematopoietic stem cells .

Cat. No.	Product Name

HY-L025

Anti-Cancer Compound Library	10,664 compounds
Cancer is the second leading cause of death globally and seriously threatens human health. A neoplasm and malignant tumor are other common names for cancer. Disruption of the normal regulation of cell-cycle progression and division lies at the heart of the events leading to cancer. Target therapy, which targets proteins that control how cancer cells grow, divide and spread, plays an important role in cancer treatment. Recent studies mainly focus on targeting the key proteins for cancer surviving, cancer stem cells, the tumor microenvironment, tumor immunology, etc. MCE designs a unique collection of 10,664 anti-cancer compounds that target kinases, cell cycle key components, tumorigenesis related signaling pathways, etc. MCE Anti-cancer compound library is a useful tool for anti-cancer drug screening.

Anti-Cancer Compound Library

10,664 compounds

Cancer is the second leading cause of death globally and seriously threatens human health. A neoplasm and malignant tumor are other common names for cancer. Disruption of the normal regulation of cell-cycle progression and division lies at the heart of the events leading to cancer. Target therapy, which targets proteins that control how cancer cells grow, divide and spread, plays an important role in cancer treatment. Recent studies mainly focus on targeting the key proteins for cancer surviving, cancer stem cells, the tumor microenvironment, tumor immunology, etc.

MCE designs a unique collection of 10,664 anti-cancer compounds that target kinases, cell cycle key components, tumorigenesis related signaling pathways, etc. MCE Anti-cancer compound library is a useful tool for anti-cancer drug screening.

HY-L058

Glycolysis Compound Library	1,258 compounds
Glycolysis is a series of metabolic processes by which one molecule of glucose is catabolized to two molecules of pyruvate with a net gain of two ATP. Glycolysis takes place in 10 steps and catalyzed by a series of enzyme, such as hexokinase, Glucose-6-phosphate isomerase, Phosphofructokinase, etc. Glycolysis is used by all cells in the body for energy generation. Most cancer cells exhibit increased glycolysis and use this metabolic pathway for generation of ATP as a main source of their energy supply. This phenomenon is known as the Warburg effect and is considered as one of the most fundamental metabolic alterations during malignant transformation. Because increased aerobic glycolysis is commonly seen in a wide spectrum of human cancers, development of novel glycolytic inhibitors as a new class of anticancer agents is likely to have broad therapeutic applications. MCE provides a unique collection of 1,258 glycolysis compounds that mainly target hexokinase, glucokinase, enolase, pyruvate kinase, PDHK, etc. MCE Glycolysis Compound Library is a useful tool for glucose metabolism research and anti-cancer drug discovery.

Glycolysis Compound Library

1,258 compounds

Glycolysis is a series of metabolic processes by which one molecule of glucose is catabolized to two molecules of pyruvate with a net gain of two ATP. Glycolysis takes place in 10 steps and catalyzed by a series of enzyme, such as hexokinase, Glucose-6-phosphate isomerase, Phosphofructokinase, etc. Glycolysis is used by all cells in the body for energy generation.

Most cancer cells exhibit increased glycolysis and use this metabolic pathway for generation of ATP as a main source of their energy supply. This phenomenon is known as the Warburg effect and is considered as one of the most fundamental metabolic alterations during malignant transformation. Because increased aerobic glycolysis is commonly seen in a wide spectrum of human cancers, development of novel glycolytic inhibitors as a new class of anticancer agents is likely to have broad therapeutic applications.

MCE provides a unique collection of 1,258 glycolysis compounds that mainly target hexokinase, glucokinase, enolase, pyruvate kinase, PDHK, etc. MCE Glycolysis Compound Library is a useful tool for glucose metabolism research and anti-cancer drug discovery.

Cat. No.	Product Name	Target	Research Area	Image